Insmed, Inc. $INSM Shares Purchased by Sei Investments Co.

Sei Investments Co. grew its position in Insmed, Inc. (NASDAQ:INSM) by 56.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,395,794 shares of the biopharmaceutical company’s stock after purchasing an additional 505,624 shares during the period. Sei Investments Co.’s holdings in Insmed were worth $228,239,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after buying an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. grew its holdings in Insmed by 2.3% in the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after buying an additional 475,832 shares in the last quarter. State Street Corp increased its position in Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after acquiring an additional 1,217,390 shares during the period. RTW Investments LP increased its position in Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after acquiring an additional 1,758,321 shares during the period. Finally, Geode Capital Management LLC raised its stake in Insmed by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after acquiring an additional 539,625 shares in the last quarter.

Insider Buying and Selling at Insmed

In other news, insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the completion of the sale, the insider owned 37,648 shares in the company, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $117.40, for a total value of $1,256,062.60. Following the sale, the chief executive officer owned 259,058 shares of the company’s stock, valued at $30,413,409.20. This trade represents a 3.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 54,590 shares of company stock valued at $5,793,738. 2.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on INSM shares. Roth Capital reiterated a “buy” rating on shares of Insmed in a research report on Monday, June 8th. Wells Fargo & Company raised their price target on Insmed from $160.00 to $161.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. cut their price objective on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Friday, July 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $209.13.

Insmed Stock Performance

NASDAQ:INSM opened at $106.64 on Thursday. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average of $105.41 and a 200-day moving average of $134.22. The firm has a market cap of $23.11 billion, a price-to-earnings ratio of -18.55 and a beta of 0.78.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter in the previous year, the company posted ($1.42) EPS. The business’s revenue was up 229.7% compared to the same quarter last year. Analysts forecast that Insmed, Inc. will post -2.43 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.